A Lipid Nanoparticle System Improves siRNA Efficacy in RPE Cells and a Laser-Induced Murine CNV Model
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
PURPOSE: To explore the possibility of the PEGylated liposome-protamine-hyaluronic acid nanoparticles (PEG-LPH-NP) loaded with siRNA (PEG-LPH-NP-S) in ARPE19 cells and a laser-induced rat model for the treatment of choroidal neovascularization (CNV). METHODS: PEG-LPH-NP-S was characterized by dynamic light scattering and transmission electron microscopy (TEM). The encapsulation efficiency of siRNA in PEG-LPH-NP was analyzed by ultracentrifugation, whereas the protection of siRNA by PEG-LPH-NP was evaluated by electrophoresis. Human RPE cells (ARPE19) were used as the cell model for the studies of cellular uptake and the inhibition of VEGFR1 expression, visualized by a laser scanning confocal microscope. The area of CNV in the laser-induced rat model after intravitreous injection was measured. The distribution of the lipid nanoparticles in the retina after intravitreous administration was investigated by fluorescence microscopy. Finally, the TUNEL test and morphologic observation of the retina were conducted. RESULTS: It was indicated that PEG-LPH-NP-S was approximately 132 nm in particle size with a positive charge of approximately 20 mV, whereas the encapsulation efficiency of siRNA in PEG-LPH-NP was >95%. PEG-LPH-NP could protect the siRNA load and could facilitate the intracellular delivery of fluorescein-labeled siRNA to ARPE19 cells. VEGFR1 expression in ARPE19 cells could be inhibited, and the CNV area in the murine model could be reduced more effectively by PEG-LPH-NP-S compared with naked siRNA and by PEG-LPH-NP with negative siRNA. It seems that the toxicity of PEG-LPH-NP-S on the rat retina is low, based on the results of TUNEL testing and morphologic observation. CONCLUSIONS: PEG-LPH-NP may be a promising lipid nanoparticle system for the siRNA treatment of CNV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [89]
Citations
Cites
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Evidence for the role of proteoglycans in cation-mediated gene transfer.
Mislick, K. A., & Baldeschwieler, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12349 · Cited by 772
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 716
Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Bressler, N. M. (2004) · JAMA · doi:10.1001/jama.291.15.1900 · Cited by 684
Reich, S. J., Fosnot, J., Kuroki, A. M., Tang, W., Yang, X., Maguire, A. M., Bennett, J., & Tolentino, M. J. (2003) · PubMed · Cited by 486
Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice
Sørensen, D. R., Leirdal, M., & Sioud, M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00181-5 · Cited by 464
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302641 · Cited by 307
Self-citation
Cited by
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Subrizi, A., del Amo, E. M., Korzhikov-Vlakh, V., Tennikova, T., Ruponen, M., & Urtti, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.001 · Cited by 239
Koo, H., Moon, H., Han, H., Na, J. H., Huh, M. S., Park, J. H., Woo, S. J., Park, K. H., Chan Kwon, I., Kim, K., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.030 · Cited by 214
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Nanotherapy for posterior eye diseases
Kaur, I. P., & Kakkar, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.031 · Cited by 175
Ocular Complications of Diabetes and Therapeutic Approaches
Vieira-Potter, V. J., Karamichos, D., & Lee, D. J. (2016) · BioMed Research International · doi:10.1155/2016/3801570 · Cited by 167
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Nano-ophthalmology: Applications and considerations
Kamaleddin, M. A. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.02.007 · Cited by 120
Zhang, J., Jiao, J., Niu, M., Gao, X., Zhang, G., Yu, H., Yang, X., & Liu, L. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s329831 · Cited by 101
Nanomedicine and drug delivery to the retina: current status and implications for gene therapy
Tawfik, M., Chen, F., Goldberg, J. L., & Sabel, B. A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02287-3 · Cited by 101
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
“Lipid nanoparticles have also been used to improve the efficiency of siRNA delivery in RPE cells and a laser-induced rat model for the treatment of choroidal neovascularization [10].”
BackgroundNanoparticles in the ocular drug delivery.
Zhou, H., Hao, J., Wang, S., Zheng, Y. F., & Zhang, W. (2013) · PubMed · doi:10.3980/j.issn.2222-3959.2013.03.25 · Cited by 90
Delplace, V., Payne, S. L., & Shoichet, M. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.065 · Cited by 89
Intravitreal nanoparticles for retinal delivery
Huang, X., & Chau, Y. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.005 · Cited by 86
Barriers to Liposomal Gene Delivery: from Application Site to the Target.
Saffari, M., Moghimi, H. R., & Dass, C. R. (2016) · PubMed Central · Cited by 79
Gene delivery nanoparticles to modulate angiogenesis
Kim, J., Mirando, A. C., Popel, A. S., & Green, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.003 · Cited by 79
A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium
Koirala, A., Conley, S. M., & Naash, M. I. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.002 · Cited by 71
Intravitreal drug delivery in retinal disease: are we out of our depth?
Thakur, S. S., Barnett, N. L., Donaldson, M. J., & Parekh, H. S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927864 · Cited by 62
Evolution of Nanotechnology in Delivering Drugs to Eyes, Skin and Wounds via Topical Route
Raghu, P. K., Bansal, K. K., Thakor, P., Bhavana, V., Madan, J., Rosenholm, J. M., & Mehra, N. K. (2020) · Pharmaceuticals · doi:10.3390/ph13080167 · Cited by 64
Videira, M., Arranja, A., Rafael, D. F. D. S., & Gaspar, R. S. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.11.018 · Cited by 63
Innovative Strategies for Drug Delivery to the Ocular Posterior Segment
Gabai, A., Zeppieri, M., Finocchio, L., & Salati, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071862 · Cited by 62
Using drug-excipient interactions for siRNA delivery
Bruno, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.003 · Cited by 60
Nanoparticulate drug delivery to the retina
Li, Q., Weng, J., Wong, S. N., Thomas Lee, W. Y., & Chow, S. F. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00224 · Cited by 59
Ocular Delivery of Therapeutic Proteins: A Review
Shastri, D. H., Silva, A. C., & Almeida, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010205 · Cited by 59
Yu, J., Jia, J., Guo, X., Chen, R., & Feng, L. (2017) · Placenta · doi:10.1016/j.placenta.2017.07.360 · Cited by 59
Patil, S., Bhatt, P., Lalani, R., Amrutiya, J., Vhora, I., Kolte, A., & Misra, A. R. (2016) · RSC Advances · doi:10.1039/c6ra24058e · Cited by 54
Dávalos, A., Henriques, R., Latasa, M. J., Laparra, M., & Coca, M. A. (2019) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2019.en-1688 · Cited by 54
Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 53
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 53
Eriksen, A. Z., Brewer, J. R., Andresen, T. L., & Urquhart, A. J. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.03.003 · Cited by 53
Amato, R., Giannaccini, M., Monte, M. D., Cammalleri, M., Pini, A., Raffa, V., Lulli, M., & Casini, G. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00144 · Cited by 52
Nanodiagnostics and Nanotherapeutics for age-related macular degeneration
Sarkar, A., & Dyawanapelly, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.054 · Cited by 51
Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers
Thakur, A., Fitzpatrick, S. D., Zaman, A., Kugathasan, K., Muirhead, B. B., Hortelano, G., & Sheardown, H. D. (2012) · Journal of Biological Engineering · doi:10.1186/1754-1611-6-7 · Cited by 50
Reynolds, J. L., Law, W., Mahajan, S. D., Aalinkeel, R., Nair, B. B., Sykes, D. E., Yong, K., Hui, R., Prasad, P. N., & Schwartz, S. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9379-7 · Cited by 49
Nanoparticles for the treatment of ocular neovascularizations
Hennig, R., & Göpferich, A. M. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.027 · Cited by 48
Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells
Jiang, W., Xiao, D., Wu, C., Yang, J., Peng, X., Chen, L., Zhang, J., Zha, G.-F., Li, W., Ju, R., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102258 · Cited by 44
Wang, J.-L., Liu, Y., Li, Y., Dai, W., Guo, Z., Wang, Z., & Zhang, Q. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9955 · Cited by 42
Self-citationBayat, F., Hosseinpour-Moghadam, R., Mehryab, F., Fatahi, Y., Shakeri, N., Dinarvand, R., ten Hagen, T. L. M., & Haeri, A. (2020) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102121 · Cited by 40
siRNA delivery for treatment of degenerative diseases, new hopes and challenges
Zahir‐Jouzdani, F., Mottaghitalab, F., Dinarvand, M., & Atyabi, F. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.04.001 · Cited by 39
Patil, S., Lalani, R., Bhatt, P., Vhora, I., Patel, V., Patel, H., & Misra, A. R. (2018) · RSC Advances · doi:10.1039/c8ra06298f · Cited by 38
Huang, X., & Chau, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00992 · Cited by 37
Gene therapy for ocular diseases meditated by ultrasound and microbubbles (Review)
WAN, C., LI, F., & LI, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4054 · Cited by 36
“Intravitreal and topical delivery of liposomes to the eye have been reported (17,18); however, they have yielded low transfection efficiency in the retina and RPE.”
The utility and risks of therapeutic nanotechnology in the retina
Scheive, M., Yazdani, S., & Hajrasouliha, A. R. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211003381 · Cited by 35
Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases
Zhang, Y., Shi, Y., Khan, M. M., Xiao, F., Chen, W., Tao, W., Yao, K., & Kong, N. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.05.002 · Cited by 31
Recent developments in liposomal drug delivery systems for the treatment of retinal diseases
Urquhart, A. J., & Eriksen, A. Z. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.004 · Cited by 31
Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review
Supe, S., Upadhya, A., & Singh, K. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108329 · Cited by 31
Considerations for the Human Health Risk Assessment of Externally Applied dsRNA-Based Pesticides
OECD (2023) · Series on pesticides and on biocides · doi:10.1787/54852048-en · Cited by 30
Bohley, M., Dillinger, A. E., Tamm, E. R., & Göpferich, A. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.024 · Cited by 29
Sharaf, M. G., Çetinel, S., Heckler, L. V., Damji, K. F., Unsworth, L. D., & Montemagno, C. D. (2014) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000059 · Cited by 29
Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization
Lee, J., Ryoo, N.-K., Han, H., Hong, H. K., Park, J. Y., Park, S. J., Kim, Y., Sim, C., Kim, K., Woo, S. J., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00148 · Cited by 29
Kakkar, S., Singh, M., Karuppayil, S. M., Raut, J. S., Giansanti, F., Papucci, L., Schiavone, N., Nag, T. C., Gao, N., Yu, F. X., et al. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2020.1871483 · Cited by 29
Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
Wang, J., Xi, Y., Liu, Y., Wang, Z., & Zhang, Q. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13068 · Cited by 27
Self-citationAmato, R., Monte, M. D., Lulli, M., Raffa, V., & Casini, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170717115654 · Cited by 25
The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina
Hurst, J., Adams, F., & Schnichels, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407173 · Cited by 24
Puras, G., Sesma, J. Z., Agirre, M., Díaz‐Tahoces, A., Avilés-Trigeros, M., Grijalvo, S., Eritja, R., Fernández, E., & Pedraz, J. L. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1271-5 · Cited by 23
Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration
Du, J. D., Fong, W., Caliph, S. M., & Boyd, B. J. (2016) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0299-6 · Cited by 23
Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes
Wang, T., Yu, T., Liu, Q., Sung, T., & Higuchi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102236 · Cited by 22
Micro/Nanoparticle Delivery Systems for Ocular Diseases
Halasz, K., Kelly, S. J., Iqbal, M. T., Pathak, Y. V., & Sutariya, V. B. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2018.911 · Cited by 22
Mishra, B., Wilson, D. R., Sripathi, S. R., Suprenant, M. P., Rui, Y., Wahlin, K. J., Berlinicke, C. A., Green, J. J., & Zack, D. J. (2019) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-019-00118-1 · Cited by 21
Nanoparticle‐motivated gene delivery for ophthalmic application
Mitra, R. N., Zheng, M., & Han, Z. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1356 · Cited by 21
Synthetic nanocarriers for the delivery of polynucleotides to the eye
Saraiva, S. M., Castro-López, V., Pañeda, C., & Alonso, M. J. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.001 · Cited by 21
Cheng, Z., Li, Y., Wang, K., Zhu, X., Tharkar, P., Shu, W., Zhang, T., Zeng, S., Zhu, L., Murray, M. T., et al. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108906 · Cited by 20
Torkashvand, A., Izadian, A., & Hajrasouliha, A. R. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.07.002 · Cited by 18
Advances in the development of lipid nanoparticles for ophthalmic therapeutics
Chen, S., Deng, Z., & Ji, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117108 · Cited by 17
Nanoengineering of therapeutics for retinal vascular disease
Gahlaut, N., Suarez, S., Uddin, M. I., Gordon, A. Y., Evans, S. M., & Jayagopal, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.001 · Cited by 16
siRNA Therapeutics in Ocular Diseases
Moreno‐Montañés, J., Bleau, A., Martínez, T., Vargas, B., González, M. V., & Jiménez, A. I. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_23 · Cited by 14
Bhatt, P., Kelly, S. J., & Sutariya, V. B. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0025 · Cited by 14
Polymeric Nanoparticles in Hybrid Catalytic Processing and Drug Delivery System
Rajan, R., Pal, K., Jayadev, D., Jayan, J. S., Aathira, U., Saritha, A., de Souza, F. G., Joseph, K., & Kumar, S. S. (2022) · Topics in Catalysis · doi:10.1007/s11244-022-01697-0 · Cited by 13
Zhao, J., Geng, Y., Hua, H.-R., Cun, B., Chen, Q., Xi, X., Yang, L., & Li, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2697 · Cited by 13
Zhang, J., Suo, Y., Zhang, Y., Zhang, Q., Chen, X., Xu, X., & Lu, W. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.03.015 · Cited by 13
Self-citationGrondek, J. F., Huffman, K., Lee, E. J., Cavichini, M., Warter, A., Kalaw, F. G. P., Heinke, A., Fan, R., Cheng, L., Sailor, M. J., et al. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0255 · Cited by 12
Amjad, M. W., Amin, M. C. I. M., Mahali, S. M., Katas, H., Ismail, I., Hassan, M. N. U., & Chuang, V. T. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105234 · Cited by 12
Katas, H., Raja, M. A. G., & Ee, L. C. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.828222 · Cited by 11
Nanoparticles in the Treatment of Angiogenesis-Related Blindness
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0113 · Cited by 9
Retinal Tissue Engineering: Regenerative and Drug Delivery Approaches
Aghmiuni, A. I., Keshel, S. H., Rahmani, A., Nadri, S., Sefat, F., & Lashay, A. (2022) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x17666220621153508 · Cited by 7
Hatamie, S., Shih, P., Chen, B., & Hatami, N. (2025) · Polymers for Advanced Technologies · doi:10.1002/pat.70094 · Cited by 7
Tasharrofi, N., Kouhkan, F., Soleimani, M., Soheili, Z., Atyabi, F., Javar, H. A., & Dorkoosh, F. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.12.048 · Cited by 7
Nardella, M., Pellegrini, M., Yu, A. C., Adamo, G., Mura, M., & Busin, M. (2025) · Biomolecules · doi:10.3390/biom15111592 · Cited by 5
Haddadzadegan, S., Mehdizdeh, N., Wang, X., Wong, T. T. L., & Miserez, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114841 · Cited by 5
Advances in RNA delivery to extrahepatic tissues and cells
Li, Z., Guo, S., & Huang, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115170 · Cited by 4
Assessing Toxicity of Nanoparticles: In Vitro and In Vivo Assays
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-15338-4_41 · Cited by 4
Panda, J. J., Yandrapu, S. K., Kadam, R. S., Chauhan, V. S., & Kompella, U. B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.039 · Cited by 4
Nanomedicine-Based Delivery to the Posterior Segment of the Eye: Brighter Tomorrow
Jalil, A., Kanwar, R. K., Pathak, Y. V., Mohammedawi, M. A., & Kanwar, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_11 · Cited by 4
Harnessing Liposomes for Advanced Gene Therapy: A Comprehensive Review
Vemuri, S. P., Karnati, P., Vadayar, K. P., & Singh, P. (2025) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0050 · Cited by 3
Smart Lipid-Based Drug Delivery Systems
Benito-Gallo, P., Gershkovich, P., Marlow, M., Zann, V., & Wasan, K. M. (2016) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781783267231_0010 · Cited by 3
Tavakoli, S. (2021) · Helda - University of Helsinki Institutional Repository · Cited by 3
Innovative Approaches to Antiviral Eye Drop Development: Acyclovir and Ganciclovir in Focus
Markowicz-Piasecka, M., Kaczmarek, A., Białek, K. I., Świnoga, P., Zawadzka, E., & Piechota-Urbańska, M. (2025) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/210753 · Cited by 2
孔令芸, Xin, C., Cheng, M., Ma, S., Zheng, Z., Chen, J., & Zhou, X. (2026) · Eye Discovery · doi:10.1016/j.edisc.2026.100040 · Cited by 2
Assessing Toxicity of Nanoparticles: In Vitro and In Vivo Assays
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-13188-7_41-1 · Cited by 2
Nanoparticles as drug delivery agents for managing diabetic retinopathy
Mukherjee, S., Panda, P., & Mishra, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-820557-0.00014-x · Cited by 2
Bioengineered and Regenerative Medicine Strategies for Retina Repair
Yu, L., Delplace, V., Payne, S. L., & Shoichet, M. S. (2018) · Fundamental biomedical technologies · doi:10.1007/978-3-319-98080-5_3 · Cited by 1
Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges
Li, M., Cai, S., Li, H., Cheng, Y., Ye, J., Ke, L., Han, Y., Su, M., Liu, G., & Chu, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111392 · Cited by 1
[Removal and reimplantation of the isolated ureter in the rat].
Saladié, J. M., Blasco, F.-J., Encabo, B., Bayona, S. A. T., Cos, J. M., Noureddine, M. A., & de León, I. P. (1988) · PubMed · Cited by 1
Thakur, A. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33780094
Karamichos, D. (2016) · MDPI eBooks · doi:10.3390/books978-3-03842-202-0
Diagnosis and Management of Ophthalmic Complications of Diabetes
Barkmeier, A. J., & Astafurov, K. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch21
Srivastava, A., Pradhan, B., Jit, B. P., Bharadwaj, K. K., & Rikhari, D. (2023) · Current Nanomedicine · doi:10.2174/2468187313666230822101717
Hamedani, Y. P., Hurst, J., Ritter, M. U., Weingarten, P., Skokowa, J., Schnichels, S., & Adams, F. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202500788
Metadata
- Authors
- Liu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q.
- Affiliations
- Peking University (CN)
- From the Peking University Eye Center, Peking University Third Hospital, Peking University, Beijing, China; and
- the State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- ORCID
- Zhang, Qiang
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-30
- Volume
- 52
- Issue
- 7
- Pages
- 4789
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1970980357
- Cited by
- 97
- References
- 19
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 10 · 2015: 9 · 2014: 6 · 2013: 5 · 2012: 5
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- lipid nanoparticles, siRNA delivery, choroidal neovascularization, PEGylated liposomes, protamine, hyaluronic acid, intravitreal injection, nanoparticle toxicity, retinal distribution
- MeSH terms
- Animals, Cells, Cultured, Disease Models, Animal, Humans, Liposomes, Male, Microscopy, Fluorescence, Rats, Inbred BN, Treatment Outcome, Apoptosis, Microscopy, Confocal, Choroidal Neovascularization, In Situ Nick-End Labeling, RNA, Small Interfering, Vascular Endothelial Growth Factor Receptor-1, Microscopy, Electron, Transmission, Rats, Nanoparticles, Retinal Pigment Epithelium, Young Adult, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.